1Drazner MH, Rame JE, Marino EK, et al. (2004) Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 43, 2207–2215.
2Liu CJ, Cheng YC, Lee KW, et al. (2008) Lipopolysaccharide induces cellular hypertrophy through calcineurin/NFAT-3 signalling pathway in H9c2 myocardiac cells. Mol Cell Biochem 313, 167–178.
3Papparella I, Ceolotto G, Montemurro D, et al. (2008) Green tea attenuates angiotensin II induced cardiac hypertrophy in rats by modulating reactive oxygen species production and the Src/Epidermal growth factor receptor/Akt signalling pathway. J Nutr 138, 1596–1601.
4Yao FR, Sun CW & Chang SK (2010) Morton lentil extract attenuated angiotensin II induced cardiomyocyte hypertrophy via inhibition of intracellular reactive oxygen species levels in vitro. J Agric Food Chem 58, 10382–10388.
5Takimoto E & Kass DA (2007) Role of oxidative stress in cardiac hypertrophy and remodelling. Hypertension 49, 241–248.
6Li HL, Wang AB, Huang Y, et al. (2005) Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signalling transduction pathways. Free Rad Biol Med 38, 243–257.
7Alissa EM & Ferns GA (2012) Functional foods and nutraceuticals in the primary prevention of cardiovascular diseases. J Nutr Metabol 2012, .
8Ames MK, Shigenaga MK & Hagen TM (1993) Oxidants, antioxidants and the degenerative disease of aging. Proc Natl Acad Sci U S A 90, 7915–7922.
9Stampfer MJ, Hu FB, Manson JE, et al. (2000) Primary prevention of coronary heart disease in women through diet and lifestyle. New Eng J Med 343, 16–22.
10Kaur M & Goel RK (2011) Anti-convulsant activity of Boerhaavia diffusa: plausible role of calcium channel antagonism. Evid Based Complement Alternat Med 4, 1–7.
11Srivastava R, Saluja D, Dwarakanath BS, et al. (2011) Inhibition of human cervical cancer cell growth by ethanolic extract of Boerhaavia diffusa Linn. (Punarnava) root. Evid Based Complement Alternat Med 2011, .
12Apu AS, Liza MS, Jamaluddin ATM, et al. (2012) Phytochemical screening and in vitro bioactivities of the extracts of aerial part of Boerhaavia diffusa Linn. Asian Paci J Trop Biomed 2, 673–678.
13Munasinghe TCJ, Seneviratne CK, Thabrew IM, et al. (2001) Antiradical and antilipoperoxidative effects of some plant extracts used by Sri Lankan traditional medical practitioners for cardioprotection. Phytother Res 15, 519–523.
14Agrawal M, Nandini D, Sharma V, et al. (2010) Herbal remedies for the treatment of hypertension. Int J Pharm Sci and Res 1, 1–21.
15Pari L & Satheesh AM (2004) Antidiabetic effect of Boerhaavia diffusa: effect on serum and tissue lipids in experimental diabetes. J Med Food 7, 472–476.
16Manu KA & Kuttan G (2009) Immunomodulatory activities of Punarnavine, an alkaloid from Boerhaavia diffusa. Immunopharmacol Immunotoxicol 31, 377–387.
17Sreeja S & Sreeja S (2009) An in vitro study on antiproliferative and antiestrogenic effects of Boerhaavia diffusa L. extracts. J Ethnopharmacol 126, 221–225.
18Aviello G, Canadanovic-Brunet JM, Milic N, et al. (2011) Potent antioxidant and genoprotective effects of Boeravinone G, a rotenoid isolated from Boerhaavia diffusa. Plos One 6, e19628.
19Prathapan A, Singh MK, Anusree SS, et al. (2011) Antiperoxidative, free radical scavenging and metal chelating activities of Boerhaavia diffusa L. J Food Biochem 35, 1548–1554.
20Gulati V, Harding IH & Palombo EA (2012) Enzyme inhibitory and antioxidant activities of traditional medicinal plants: potential application in the management of hyperglycemia. BMC Compl Alt Med 12, 77.
21Pareta SK, Patra KC, Mazumder PM, et al. (2011) Aqueous extract of Boerhaavia diffusa root ameliorates ethylene glycol-induced hyperoxaluric oxidative stress and renal injury in rat kidney. Pharm Biol 49, 1224–1233.
22Singleton VL & Rossi JA (1965) Colorimetry of total phenolics with phosphomolybdic-phosphotungstic acid reagents. Am J Enol Viticult 16, 144–158.
23Jia Z, Mengcheng T & Wu J (1999) The determination of flavanoid contents in mulberry and their scavenging effects on superoxide radicals. Food Chem 64, 555–559.
24Hernandez-Ledesma B, Martin-Alvarez PJ & Pueyo E (2003) Assessment of the spectrometric method for determination of angiotensin-converting enzyme activity: influence of the inhibition type. J Agri Food Chem 51, 4175–4179.
25Owen PL & Johns T (1999) Xanthine oxidase inhibitory activity of northeastern North American plant remedies used for gout. J Ethnopharmacol 64, 149–160.
26Wilson AP (2000) Cytotoxicity and viability assays. In Animal Cell Culture: A Practical Approach, 2nd ed., pp. 175–219 [Masters JRW, editor]. Oxford: Oxford University Press.
27Merten KE, Jiang Y, Feng W, et al. (2006) Calcineurin activation is not necessary for Doxorubicin-induced hypertrophy in H9c2 embryonic rat cardiac cells: involvement of the phosphoinositide 3-kinase-Akt pathway. J Pharmacol Exp Therap 319, 934–940.
28Bradford MM (1976) A rapid and sensitive method for the quantification of microgram quantities of protein, utilizing the principle of protein-dye binding. Anal Biochem 72, 248.
29Aebi H (1984) Catalase in vitro. Methods Enzymol 105, 121–127.
30Paoletti F, Aldinucci D, Mocali A, et al. (1986) A sensitive spectrophotometric method for the determination of superoxide dismutase activity in tissue extracts. Anal Biochem 154, 538–541.
31Gunzler WA, Kramers H & Flohe L (1974) An improved coupled test procedure for glutathione peroxidase. Klin Chem Klin Biochem 12, 444–448.
32Goldberg DM & Spooner RJ (1987) Glutathione reductase. In Methods of Enzymatic Analysis, pp. 258–265 [Bergmeyer HV, editor]. Weinheim: Verlag-Chemie.
33Hissin PJ & Hilf RA (1976) Fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 74, 214–226.
34Choi EH, Chang HJ, Cho JY, et al. (2007) Cytoprotective effect of anthocyanins against doxorubicin-induced toxicity in H9c2 cardiomyocytes in relation to their antioxidant activities. Food Chem Toxicol 45, 1873–1881.
35Raghu KG & Cherian OL (2009) Characterization of cytotoxicity induced by arsenic trioxide (a potent anti-APL drug) in rat cardiac myocytes. J Trace Elem Med Biol 23, 61–68.
36Chomczynski P & Sacchi N (1987) Singlet-step method of RNA isolation by acid guanidium thiocyanate–phenol–chloroform extraction. Anal Biochem 162, 156–159.
37Kimes BW & Brandt BL (1976) Properties of a clonal muscle cell line from rat heart. Exp Cell Res 98, 367–381.
38Watkins SJ, Borthwick GM & Arthur HM (2011) The H9c2 cell line and primary neonatal cardiomyocyte cells show similar hypertrophic responses in vitro. In vitro Cell Dev Biol Animal 47, 125–131.
39Hescheler J, Meyer R, Plant S, et al. (1991) Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart. Circ Res 69, 1476–1486.
40Sipido KR & Marban E (1991) L-type calcium channels, potassium channels, and novel nonspecific cation channels in a clonal muscle cell line derived from embryonic rat ventricle. Circ Res 69, 1487–1499.
41Wollert KC & Drexler H (1999) The rennin–angiotensin system and experimental heart failure. Cardiovasc Res 43, 838–849.
42Unger T (2002) The role of the renin–angiotensin system in the development of cardiovascular disease. Am J Cardiol 89, 3A–9A.
43Wang H & Joseph JA (1999) Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Rad Biol Med 27, 612–616.
44Hajjar RJ & Leopold JA (2006) Xanthine oxidase inhibition and heart failure. Circ Res 98, 169–171.
45Poljsak B (2011) Strategies for reducing or preventing the generation of oxidative stress. Oxid Med Cell Longev 2011, 194586.
46Dinu D, Bodea GO, Ceapa CD, et al. (2011) Adapted response of the antioxidant defense system to oxidative stress induced by deoxynivalenol in Hek-293 cells. Toxicon 57, 1027–1032.
47Devasagayam TPA, Boloor KK & Ramasarma T (2003) Methods for estimating lipid peroxidation: an analysis of merits and demerits. Ind J Biochem Biophys 40, 300–308.
48Nelson SK, Bose SK & McCord JM (1994) The toxicity of high-dose superoxide dismutase suggests that superoxide can both initiate and terminate lipid peroxidation in the reperfused heart. Free Radic Biol Med 16, 195–200.
49Shlafer M & Shepard BM (1984) A method to reduce interference by sucrose in the detection of thiobarbituric acid-reactive substances. Anal Biochem 137, 269–276.
50Halliwell B (1996) Oxidative stress, nutrition and health. Experimental strategies for optimization of nutritional antioxidant intake in humans. Free Radic Res 25, 57–74.
51Peng X & Li Y (2002) Induction of cellular glutathione linked enzymes and catalase by the unique chemo preventive agent, 3H-1,2-dithiole-3-thione in rat cardiomyocytes affords protection against oxidative cell injury. Pharmacol Res 45, 491–497.
52Abhilash PA, Harikrishnan R & Indira M (2012) Ascorbic acid supplementation causes faster restoration of reduced glutathione content in the regression of alcohol induced hepatotoxicity in male guinea pigs. Redox Rep 17, 72–79.
53Kent KD, Harper WJ & Bomser JA (2003) Effect of whey protein isolate on intracellular glutathione and oxidant-induced cell death in human prostate epithelial cells. Toxicol in vitro 17, 27–33.
54Ouyang X, Takahashi K, Komatsu K, et al. (2001) Protective effect of Salvia militiorrhiza on angiotensin II induced hypertrophic responses in neonatal rat cardiac cells. Jpn J Pharmacol 87, 289–296.
55Ichikawa H, Yagi H, Tanaka T, et al. (2010) Lagerstroemia speciosa extract inhibit TNF-induced activation of nuclear factor-κβ in rat cardiomyocyte H9c2 cells. J Ethnopharmacol 128, 254–256.
56Purcell NH, Tang G, Yu C, et al. (2001) Activation of NF-κβ is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci U S A 98, 6668–6673.
57Li Y, Ha T, Gao X, et al. (2004) NF-κB activation is required for the development of cardiac hypertrophy in vivo. Am J Physiol Heart Circ Physiol 287, 1712–1720.
58Baldwin AS Jr (1996) The NF-kappa B and I-kappa B proteins: new discoveries and insights. Ann Rev Immunol 14, 649–683.
59Jones WK, Brown M, Wilhide M, et al. (2005) NF κβ in cardiovascular disease. Cardiovasc Toxicol 5, 183–201.
60Li RK, Li G, Mickle DA, et al. (1997) Overexpression of transforming growth factor-beta1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation 96, 874–881.
61Schultz JJ, Witt SA, Glascock BJ, et al. (2002) TGF-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 109, 787–796.
62Yamazaki T, Yamashita N, Izumi Y, et al. (2012) The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice. Hypertension Res 35, 34–40.
63Vita JA (2005) Polyphenols and cardiovascular disease: effects on endothelial and platelet function. Am J Clin Nutr 81, 292–297.
64Ferreres F, Sousa C, Justin M, et al. (2005) Characterization of phenolic profile of Boerhaavia diffusa L. by HPLC-PAD-MS/MS as tool for quality control. Phytochem Anal 16, 451–458.
66Perez-Vizcaino F & Duarte J (2010) Flavonols and cardiovascular disease. Mol Aspects Med 31, 478–494.
67Duarte J, Jimenez R, O'Valle F, et al. (2002) Protective effects of the flavonoid quercetin in chronic nitric oxide deficient rats. J Hypertens 20, 1843–1854.
68Calderon-Montano JM, Burgos-Moron E, Perez-Guerrero C, et al. (2011) A review on the dietary flavonoid kaempferol. Mini Rev Med Chem 11, 298–344.
69Senthil S, Sridevi M & Pugalendi KV (2007) Protective effect of ursolic acid against myocardial ischemia induced by isoproterenol in rats. Toxicol Mech Methods 17, 57–65.
70Lami N, Kadota S, Kikuchi T, et al. (1991) Constituents of the roots of Boerhaavia diffusa L. III. Identification of a calcium channel antagonistic compound from the methanol extract. Chem Pharm Bull 39, 1551–1555.